This study included data from 185 consecutively treated patients, 16 years of age or older, who underwent myeloablative transplantation using unrelated umbilical cord blood (UCB) (UCB transplantation (UCBT), n = 70) or HLA-identical sibling donor peripheral blood stem cells alone or combined with bone marrow (BMT/PBSCT, n = 115) from October 2001 to December 2012. All patients received myeloablative regimens, cyclosporin A plus mycophenolate mofetil as prophylaxis for GVHD, and similar supportive care. Although hematopoietic recovery was significantly delayed after UCBT, the rate of neutrophil engraftment was comparable. The median follow-up was 53 months (range, 15-136 months) for BMT/peripheral blood SCT (PBSCT) recipients and 35 months (range, 10-123 months) for UCBT recipients. There were no significant differences in the cumulative incidence of grades III to IV acute GVHD, relapse rate, or 3-year probabilities of disease-free survival between patients receiving UCBT and those receiving BMT/PBSCT. However, the cumulative incidence of chronic and extensive chronic GVHD was lower in UCBT recipients. The rates of long-term survivors returning to school or work and off immunosuppressive therapy were significantly higher after UCBT, which indicated that long-term survivors who underwent UCBT had a higher quality of life.
INTRODUCTION
Allogeneic hematopoietic SCT is an established curative therapy for many hematologic malignancies. Hematopoietic SCT (HSCT) from an HLA-matched sibling donor (MSD) is the gold standard; 1 however, transplant centers must search for an alternative donor for~70% of patients who lack an MSD but require allo-HSCT. Over the past 20 years, the clinical outcome after HSCT from all alternative donor types has improved owing to advances in HSCT technology. [2] [3] [4] [5] [6] [7] [8] [9] [10] Both acute and chronic GVHD (cGVHD) occur more frequently following alternative donor HSCT methods, [11] [12] [13] [14] with the exception of umbilical cord blood transplantation (UCBT), 15, 16 and often adversely affect quality of life (Qol) and OS. Although a high risk of graft failure and early treatment-related complications are still major issues, improvements have been made in the selection of UCB units, 17, 18 the safety of preparative therapies, 9, 19 and the process of salvage haplo-stem cell transplantation, [20] [21] [22] which have increased the engraftment rate and decreased early mortality from UCBT. A low risk of GVHD and relapse after UCBT compared with other donor sources further enhances the appeal of UCBT for patients with high-risk hematopoietic malignances. 15, 16 At our institution, over the last decade, UCBT has been used as the first alternative option for patients who lack an HLA-matched related donor. We retrospectively analyzed the clinical outcomes of UCBT vs MSD transplantation for adult patients with hematologic malignancies.
MATERIALS AND METHODS

Patient and donor selection
The study included data from 185 consecutively treated patients who underwent myeloablative HSCT using unrelated UCB (n = 70) or MSD peripheral blood stem cells alone or combined with bone marrow (n = 115) at the Affiliated Provincial Hospital of Anhui Medical University from 1 October 2001 to 31 December 2012. All patients were 16 years of age or older and suffered from a hematological malignancy requiring allo-SCT. Patients who received a previous transplantation, a related HLAmismatched transplantation or an unrelated adult donor transplantation were excluded. The Anhui Medical University Institutional Review Board approved the transplantation protocol, and all patients included in the study provided informed consent.
The siblings of each patient were checked first during the donor search. If a patient had no MSD and suitable UCB was available, we generally accepted UCBT as the first treatment option. HLA-A and HLA-B antigens were identified by serologic typing. HLA-DRB1 alleles were determined by high-resolution molecular typing. Anti-HLA antibody screening was not performed. Cord blood units were obtained through the Chinese Cord Blood Bank Network.
Conditioning regimen, GVHD prophylaxis and treatment, and supportive care
All patients received fully myeloablative conditioning regimens, which are summarized in Table 1 . In the UCBT group, 65 (92.9%) patients received TBI-based conditioning, and five (7.1%) patients received Bu-based conditioning. In the sibling BMT/peripheral blood stem cell transplantation 1 (PBSCT) group, 85 (73.9%) patients received Bu-CY and 30 (26.1%) patients received TBI-CY conditioning; the doses of TBI, CY and Bu were the same as those in the UCBT group, but Ara-C and fludarabine were omitted. None of the patients in the two groups received antithymocyte globulin (ATG) as part of the conditioning regimen.
All patients were given a combination of CsA (Stein, Switzerland) and mycophenolate mofetil (MMF) (Shanghai Roche Pharmaceuticals Ltd, Shanghai, China) for GVHD prophylaxis, as previously described. 23 Corticosteroid-based treatment was considered when pre-engraftment syndrome (PES) and grade II or higher acute GVHD (aGVHD) occurred (0.5-2 mg/kg). If the manifestations of GVHD in any organ worsened over 3 days of treatment or if the skin did not improve by 5 days, second-line treatments were used, such as anti-CD25 monoclonal antibody (basiliximab), methotrexate and mesenchymal stem cells. Each patient was isolated in a room equipped with a laminar airflow system. The supportive care regimen, including prophylaxis for infection, G-CSF use and blood product infusion, was the same as previously reported. 23 
Definitions
Neutrophil engraftment was defined as the achievement of an ANC ⩾ 0.5 × 10 9 /L for three consecutive days, and platelet recovery was defined as the achievement of a platelet count ⩾ 20 × 10 9 /L unsupported by platelet transfusions for 7 days. Primary graft failure was defined as the failure to reach an ANC ⩾ 0.5 × 10 9 /L for at least 3 consecutive days on day 35 following transplantation based on chimerism analysis using polymorphic genetic markers. The assessment of PES, grading of aGVHD and grading of cGVHD was performed according to standard criteria. [24] [25] [26] Patients surviving in remission for least 100 days after transplantation were regularly evaluated for cGVHD. Relapse was defined based on morphological evidence of disease in the peripheral blood, marrow or extramedullary sites. Non-relapse mortality (NRM) was defined as death after HSCT without disease progression or relapse. The OS was measured from the time of HSCT to the time of death from any cause or last recorded followup. Post-transplant disease-free survival (DFS) was defined as the time interval from HSCT to relapse, death or the last contact.
Statistical analysis
The primary endpoint of the study was to compare the OS and DFS rates between the UCB and MSD groups. Other endpoints included the cumulative incidences of neutrophil and platelet engraftment, aGVHD and cGVHD, relapse and NRM. The Mann-Whitney non-parametric U-test and Student's t-test were used to analyze differences in the continuous variables. All tests were two-sided, and Po 0.05 was considered statistically significant. Survival probabilities were estimated using the Kaplan-Meier method. Engraftment, aGVHD, cGVHD, relapse and NRM were estimated as cumulative incidences, taking into account competing risks. The data analyses were primarily performed using SPSS software, version 13.0 (SPSS Inc., Chicago, IL, USA). Endpoints were calculated at the last contact, and the date of the final follow-up was 30 October 2013.
RESULTS
Characteristics of patients and grafts
The characteristics of patients and transplants are illustrated in Table 1 . The patients' sex, body weight, diagnosis, extent of ABO match and GVHD prophylaxis regimens were almost the same between the BMT/PBSCT and UCBT recipients. On the other hand, there were considerable differences between these two groups with respect to the recipients' ages at transplantation, the extent of HLA match, high-risk disease status, cell dose and type of conditioning. Patients receiving UCBT were younger and were more likely to have a high-risk disease status. Additionally, UCBT recipients received more TBI-based conditioning regimens, while the BMT/PBSCT recipients were more likely to receive a Bu-based conditioning regimen without Ara-C or Flu (P = 0.000). The characteristics of recipients and grafts are described in Table 1 . In the UCBT group, 22 patients received double UCB units, whereas 48 patients received a single UCB unit.
Neutrophil and platelet engraftment None of the patients in this study died within 28 days of transplantation. Two patients experienced Primary graft failure after UCBT: one survived after a second transplantation, and the other had autologous reconstitution without relapse. The primary engraftment rates were 97% (UCBT) and 100% (BMT/PBSCT).
Patients receiving UCBT showed significantly slower neutrophil and platelet recovery in multivariate analysis ( Table 2 ). The incidence of neutrophil recovery by day 42 was 97.1% (95% confidence interval [CI] 97.0-97.2%; Figure 1a ) in the UCBT recipients and 100% in the BMT/PBSCT recipients (P = 0.08). Ten patients died between 40 and 109 days after UCBT without platelet engraftment. The cumulative incidence of platelet recovery at day 150 was 81.4% (95% CI, 80.9-81.9%; Figure 1b ) in UCBT recipients and 100% in MSD Abbreviations: MDS = myelodysplastic syndrome; ML = malignant lymphoma; MMF = mycophenolate mofetil; MPAL = mixed phenotype acute leukemia; MRD = matched related donor; PBSC = peripheral blood stem cells; UCB = unrelated cord blood. a Patients were considered high-risk if they had high-risk cytogenetic abnormalities, a high-white blood cell count at diagnosis, malignancy beyond the first complete remission or first chronic phase (CR1/CP1), or MDS with refractory anemia. transplant recipients (P = 0.000). The use of BMT/PBSCT was significantly associated with a higher incidence of platelet engraftment and a comparable incidence of neutrophil engraftment.
PES and GVHD Of the 70 patients eligible for analysis in the UCB group, 39 (55.7%) patients developed PES at a median of 7 days (range, 5-12 days). None of the 115 patients in the BMT/PBSCT group experienced PES (P = 0.000). The incidences of grade II-IV aGVHD in the UCBT group were significantly higher than those in the BMT/PBSCT group (odds ratio, 3.80; 95% CI, 1.87-7.70; P = 0.000). However, the incidence of grade III-IV aGVHD in both groups was almost equivalent (odds ratio, 2.53; 95% CI, 0. (Figure 2a) . The incidence of NRM in the UCBT recipients was significantly higher than that in the BMT/PBSCT recipients according to univariate analysis (P = 0.04). In multivariate regression analysis, the donor type did not have a significant effect on the NRM; however, severe aGVHD (grades III-IV), cGVHD and extended cGVHD had significant impacts on the NRM (Table 3) . Abbreviations: IST = immunosuppressant therapy; PBSCT = peripheral blood SCT; PES = pre-engraftment syndrome; UCBT = umbilical cord blood transplantation.
a The hazard ratio is for cord blood transplantation compared with bone marrow and/or peripheral blood stem cell transplantation. Sibling allo-PBSCT/BMT Unrelated CBT P-0.0000 Figure 1 . Cumulative incidence of neutrophil (a) and platelet (b) engraftment after transplantation. Engraftment rates were calculated by taking into account the competing risk of death before engraftment. The use of BMT/PBSCT was significantly associated with a higher incidence of platelet engraftment (P = 0.000) and a comparable incidence of neutrophil engraftment (P = 0.08). Patients receiving UCBT had significantly slower neutrophil and platelet recovery in multivariate analysis (P = 0.000).
The 3-year cumulative incidences of relapse were 11.91% (95% CI, 11.59-12.22%) among the UCBT recipients and 16.19% (95% CI, 15.95-16.44%) among the BMT/PBSCT recipients. There was no apparent difference in the risk of relapse between the two groups in univariate analysis (Figure 2b , P = 0.50). In multivariate analysis, the only adverse factor that had a significant impact on the risk of relapse was high-risk disease (hazard ratio, 8.37; 95% CI, 2.17-32.24; P = 0.002). cGVHD and aGVHD had no significant protective effect on the rate of relapse in our study (Table 3) .
Survival and QoL
The 3-year probabilities of DFS and OS were similar between the two groups. The 3-year probabilities of the Kaplan-Meierestimated DFS were 55% (95% CI, 43-67%) after UCBT and 60% (95% CI, 51-69%) after BMT/PBSCT (P = 0.105, Figure 3a) . The DFS in both groups was equivalent in standard-risk and high-risk patients. The 3-year probabilities of DFS were 80% (95% CI, 55-100%) after UCBT and 77% (95% CI, 66-87%) after BMT/PBSCT in recipients in the standard-risk category (Figure 3b) . The 3-year probabilities of DFS in recipients in the high-risk category were 50% (95% CI, 37-63%) after UCBT and 46% (95% CI, 33-59%) after BMT/PBSCT. By pairwise comparison, the DFS was significantly better for standard-risk recipients vs high-risk recipients in the BMT/PBSCT group (P = 0.001); however, it was similar for standardrisk recipients vs high-risk recipients in the UCBT group (P = 0.124). In multivariate Cox regression analysis, the DFS was similar between the two groups (hazard ratio, 0.67; 95% CI, 0.28-1.60; P = 0.668). The adverse covariates that were significant in the final DFS model include relapse, high-risk disease, severe aGVHD and severe cGVHD (Table 3 ). The main causes of post-transplantation death were infection, GVHD and leukemia relapse. Patients in the UCBT cohort were more likely to die from infection and aGVHD with infection compared with patients in the BMT/PBSCT cohort. Patients in the BMT/PBSCT cohort were more likely to die from cGVHD with infection and primary disease (data not shown).
On 30 October 2013, the median duration of follow-up was 35 months (range, 10-123 months) for the surviving UCBT recipients and 53 months (range, 15-136 months) for the surviving BMT/PBSCT recipients. In total, 36 of the 38 surviving patients in the UCBT group were free from immunosuppressive therapy (IST), and the IST discontinuation rate at 1 year was 94.7% Figure 2 . Cumulative incidence of non-relapse mortality (NRM) (a) and relapse rate (b) after transplantation. The relapse rate was calculated by taking into account the competing risk of death owing to NRM. There was no apparent difference in the risk of relapse at 3 years in UCBT recipients vs BMT/PBSCT recipients (Gray test, P = 0.50). Abbreviations: DFS = disease-free survival; NRM = non-relapse mortality, UCBT = umbilical cord blood transplantation. DFS = UCBT = 1, BMT/PBSCT = 0; acute GVHD (II-IV), yes = 1, no = 0; Grade III-IV aGVHD, yes = 1, no = 0; chronic GVHD, yes = 1, no = 0; relapse, yes = 1, no = 0; high-risk disease = 1, standard-risk disease = 0; TBI-based conditioning = 1, Bu-based conditioning = 0.
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among the surviving patients. All but two patients with chronic liver and oral GVHD had Karnofsky scores of 80-100 and returned to school or work full time within 18 months after UCBT. However, in the BMT/PBSCT group, 32 of 83 patients (38%) who were alive for more than 1 year were still on systemic IST to control cGVHD, and 50 of 83 patients (60%) returned to school or work (P = 0.000).
The proportion of patients who were alive for more than 1 year, suffered cGVHD, and did not return to work was smaller in the UCBT group compared with the BMT/PBSCT group (Table 2) .
DISCUSSION
Despite the growth in the use of UCBT worldwide, information on the outcomes of UCBT for the treatment of hematologic malignances in adults in China is still very limited. In this retrospective, single-center study, we compared transplantation outcomes after UCBT and HLA-matched sibling BMT/PBSCT in adults with hematologic malignances. The main aim of the study was to evaluate whether UCB should be used as a primary stem cell source for adult recipients with hematologic malignances if they lack an HLA-matched related donor. At our center, all patients received the same GVHD prophylaxis and supportive care. The groups differed in their initial characteristics: the UCBT recipients were younger and significantly more likely to have high-risk disease, and they received more TBIbased and intensified conditioning regimens. However, we performed a carefully controlled analysis and adjusted for the relevant clinical characteristics, which allowed us to compare the transplant outcomes across the two treatment groups.
Engraftment after UCBT remains a major concern for adult subjects. Our results showed that hematopoietic recovery was delayed after UCBT compared with BMT/PBSCT. However, the rate of neutrophil recovery did not differ between the UCBT and BMT/ PBSCT recipients, which was consistent with the results of Takahashi et al. 16 and somewhat higher than the rates reported in European and American studies. [27] [28] [29] A plausible reason for the higher rate of hematopoietic recovery in the UCBT group in our study might be the availability of grafts containing higher number of cells (median, 3.6 × 10 7 /kg) as well as better HLA matching (67% of patients had a complete HLA match or mismatch at only one locus). Additionally, engraftment also appears to be significantly influenced by the preparative regimen. We observed a favorable engraftment rate with a majority of our patients using TBI − CY plus cytarabine as a conditioning regimen before UCBT, which is similar to what was observed in a Japanese study. 9, 16 The engraftment rate with the Cy-TBI regimen was significantly better than that achieved with the Bu-Cy regimen in unrelated BMT, as described in a previous report. 30 In the present study, the incidence of grade II-IV aGVHD in the UCBT group (nearly 40%) was similar to that reported in a Japanese study (52%); 16 however, it was higher than that reported in European and American studies (24-34%). 27, 28 This difference might reflect variations in the GVHD prophylaxis regimens and immunogenetic diversity. In Europe and the US, GVHD prophylaxis regimens in UCBT cohorts mostly consist of CsA or tacrolimus in combination with glucocorticoids and ATG. In contrast, CsA in combination with short-term MTX was a common GVHD prophylaxis regimen in Japan in UCBT recipients. Similar to the Japanese study, we omitted ATG, and we used MMF instead of MTX, which appears to be more effective in GVHD prophylaxis. The incidence of grades II-IV aGVHD (14.7%) was low in response to this regimen in the sibling BMT/PBSCT group. However, because the Japanese population is relatively genetically homogeneous, the cumulative incidence of severe aGVHD and the incidence of clinically significant aGVHD requiring systemic glucocorticoid therapy were very low in Japan, which contributed to the reduced risk of early NRM in the UCBT recipients. 9, 16 As observed in previous studies, compared with BMT/PBSCT, UCBT was associated with identical or lower rates of cGVHD and extensive cGVHD with or without the use of ATG. 10, 16, 27, 31 Our results also indicated that the rates of cGVHD and extensive cGVHD were lower in the UCBT group despite the omission of ATG in the conditioning regimen. Mild and infrequent cGVHD was observed in the UCBT survivors, which was comparable to data reported previously. 16, 27, 32 Additionally, all of the long-term survivors, with the exception of two individuals, were off IST and were able to return to school or work following UCBT, whereas of the BMT/PBSCT recipients who survived for more than 1 year, 61% were off IST and 60% were able to return to work. cGVHD was the factor that most adversely affected QoL, while stopping IST and returning to work had a crucial positive effect on QoL. [33] [34] [35] [36] Therefore, our results suggest that long-term survivors who underwent UCBT had better QoL.
Although more patients in the UCBT group had high-risk disease (87% in the UCBT group vs 47% in the BMT/PBSCT group), the risk of relapse was proportionally lower in UCBT recipients than in the BMT/PBSCT patients in the present study. UCBT was associated with a low-relapse rate and less cGVHD, which appears to be due to the separation of GVHD and GVL in the UCBT group. In addition, the intensity of conditioning has a crucial role in UCBT with standard-risk disease Figure 3 . The 3-year Kaplan-Meier estimate of disease-free survival (DFS) after transplantation in the two groups. (a) The 3-year probabilities of DFS as estimated by Kaplan-Meier analysis were 55% (95% CI, 43-67%) after UCBT and 60% (95% CI, 51-69%) after BMT/PBSCT. The differences between the two groups were not significant (P = 0.105). (b) The 3-year Kaplan-Meier estimate of DFS in patients with standard-risk disease and high-risk disease in the two groups. The differences between the two groups with standard-risk disease (P = 0.850) or high-risk disease (P = 0.074) were not significant.
reducing relapse. 9, 16 Compared with the BMT/PBSCT recipients in the current study, most of the UCBT patients received TBI-based conditioning and further intensification of conditioning with the administration of additional antileukemic agents, such as Ara-C, which may have contributed to less relapse. The main limitations of the present study were that it was retrospective in nature with a small sample size, including patients from a single institution.
In summary, we compared the clinical outcomes of UCBT in unrelated donors with BMT/PBSCT in HLA-identical sibling donors, and we found that the 3-year DFS and OS rates were equivalent in the two groups. Remarkably, the long-term survivors in the UCBT group had less cGVHD and a higher QoL, which is important to consider when choosing a donor type.
